“Review (Natural Medicines Comprehensive Database): There is some evidence that taking combined high-dose melatonin with conventional chemotherapy or with interleukin-2 (IL-2) might improve tumor regression rate in patients with breast cancer, lung cancer, kidney cancer, liver cancer, pancreatic cancer, stomach cancer, or colon cancer (1692,5854,5855,5857,7040,7043,8268). Melatonin plus chemotherapy in patients with metastatic solid tumors seems to increase regression rate and one-year survival rate by approximately 50% compared to chemotherapy alone (7040). The addition of melatonin also seems to help reduce chemotherapy toxicities, including hematologic complications, cachexia, asthenia, and neuropathy (8268). There is also some preliminary evidence that melatonin alone, orally or intramuscularly, might improve stabilization rate and possibly one-year survival rate in patients with resistant or untreatable lung neoplasms, liver neoplasms, pancreas neoplasms, colon neoplasms, breast neoplasms, and brain neoplasms (1080,1688,1693,2566).
[Read the rest of this entry...]